IP Library › Granted Patent US 12,447,159
Granted Patent B2
US 12,447,159 · App. 17/945,339 · Granted Oct 21, 2025

3β-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders

Inventors: Pier Vincenzo Piazza (Bordeaux, FR); Sandy Fabre (Bordeaux, FR); Mathilde Metna (Bordeaux, FR); Stephanie Monlezun (Bordeaux, FR); Arnau Busquet-Garcia (Bordeaux, FR); Daniela Cota (Bordeaux, FR); Giovanni Marsicano (Bordeaux, FR); Jean-Michel Revest (Bordeaux, FR); Monique Vallee (Bordeaux, FR)
Assignees: AELIS FARMA; INSERM (Institut National de la Santé et de la Recherche Médicale); UNIVERSITE DE BORDEAUX
A61K31/57A61P25/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,159
App. No.
17/945,339
Granted
Oct 21, 2025
Kind
B2
Abstract

The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

Claims (25)

1. A method for treating a Cannabinoids-Related Disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Formula (I):

wherein the compound is administered to the subject at a dose between 10 g to 10 mg.

2. The method of claim 1 , wherein the compound is administered to the subject at a dose between 10 μg to 5 mg.

3. The method of claim 1 , wherein the compound is administered to the subject at a dose between 10 μg to 1 mg.

4. The method of claim 1 , wherein the compound is administered to the subject at a dose between 10 μg to 600 μg.

5. The method of claim 1 , wherein the compound is administered to the subject at a dose between 10 μg to 200 μg.

6. The method of claim 1 , wherein the compound is administered to the subject at a dose between 10 μg to 100 μg.

7. The method of claim 1 , wherein the compound is administered to the subject from 1 to 4 times per day.

8. The method of claim 7 , wherein the dose is administered to the subject 1 time per day.

9. The method of claim 1 , wherein the Cannabinoids-Related Disorder is selected from the group consisting of Cannabinoids Use Disorder, Cannabinoids Intoxication, Cannabinoids Withdrawal, Other Cannabinoids-Induced Disorder, Unspecified Cannabinoids-Related Disorder, Cannabinoids Hyperemesis Syndrome, and Cannabinoids-Induced Catatonia.

10. The method of claim 9 , wherein the Cannabinoids-Related Disorder is Cannabinoids Use Disorder.

11. The method of claim 9 , wherein the Cannabinoids-Related Disorder is Cannabinoids Intoxication.

12. The method of claim 9 , wherein the Cannabinoids-Related Disorder is Cannabinoids Withdrawal.

13. The method of claim 9 , wherein the Cannabinoids-Related Disorder is an Other Cannabinoids-Induced Disorder selected from the group consisting of cannabinoids-induced anxiety disorder, cannabinoids-induced psychotic disorder, cannabinoids-induced sleep disorder, and cannabinoids intoxication delirium.

14. The method of claim 9 , wherein the Cannabinoids-Related Disorder is an Unspecified Cannabinoids-Related Disorder.

15. The method of claim 9 , wherein the Cannabinoids-Related Disorder is a Cannabinoids Hyperemesis Syndrome.

16. The method of claim 9 , wherein the Cannabinoids-Related Disorder is a Cannabinoids-Induced Catatonia.

17. The method of claim 1 , wherein the Cannabinoids-Related Disorder is a disorder associated with the use of cannabinoids derived from a Cannabis L. plant.

18. The method of claim 1 , wherein the Cannabinoids-Related Disorder is a disorder associated with the use of a synthetic cannabinoid with CB1 agonist activity.

19. The method of claim 1 , wherein the compound is administered to the subject via an oral route.

20. The method of claim 1 , wherein the compound is administered to the subject via a parenteral route either with a readily absorbable formulation or a depot-type formulation.

21. The method of claim 1 , wherein the compound is administered intravenously, subcutaneously, or intramuscularly.

22. The method of claim 1 , wherein the compound is administered intranasally, by inhalation, sublingually, topically, transdermally, or in the form of a suppository or pessary.

23. The method of claim 1 , wherein the compound is administered in an oleaginous vehicle.

24. The method of claim 23 , wherein the oleaginous vehicle is a long chain triglyceride vegetable oil.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2023
From: BUSQUET-GARCIA, ARNAU; COTA, DANIELA; REVEST, JEAN-MICHEL; MARSICANO, GIOVANNI; VALLEE, MONIQUE; PIAZZA, PIER VINCENZO; MONLEZUN, STEPHANIE; FABRE, SANDY; METNA, MATHILDE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE DE BORDEAUX; AELIS FARMA
Reel/Frame 063701/0952 →
Priority Claims (1)
EP 18305177 · Feb 20, 2018 · regional
Continuity (2)
Continuation 16968237
Related Publication 20230226076A1 · Jul 20, 2023
References Cited (19)
US 10259839B2 · Piazza et al. · 2019 [cited by applicant]
US 11484537B2 · Piazza et al. · 2022 [cited by applicant]
US 20150284423A1 · Piazza et al. · 2015 [cited by applicant]
US 20210030768A1 · Piazza et al. · 2021 [cited by applicant]
WO 2012160006A1 · 2012 [cited by applicant]
WO 2014083068A1 · 2014 [cited by applicant]
Busquets-Garcia et al., “Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice, ”Molecular Psychiatry. (2017), 22(11): 1594-1603. [cited by applicant]
International Search Report and Written Opinion issued in the International Application No. PCT/EP2019/054217 dated Aug. 5, 2019. [cited by applicant]
Vallee et al., “Pregnenolone can protect the brain from cannabis intoxication,” Science Jan. 3, 2014: 343(6166):94-98. [cited by applicant]
Tait et al., “A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment,” Clin. Toxicol. (Phila). 2016; 54(1): 1-13. [cited by applicant]
Keown, A. (Dec. 5, 2019) “Sage's MDD Treatment Fails to Distinguish Itself From Placebo in Late-Stage Trial,” BioSpace. (2019), https://www.biospace.com/article/sage-plunges-after-phase-iii-setback-in-major-depressive-d… [cited by applicant]
Althaus A. L., et al., “Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator,” Neuropharmacology (2020) 181:108333. [cited by applicant]
Declaration under 37 C.F.R 1.132 filed Jun. 28, 2018 in U.S. Appl. No. 14/443,778 (now U.S. Pat. No. 10,259,839; “Piazza 1”). [cited by applicant]
“Cannabis-Related Disorders,” Diagnostic and Statistical Manual of Mental Disorders DSM-5, 5th Edition (2013) 509-519. [cited by applicant]
Howlett, A.C., “Cannabinoid Receptor Signaling,” Neuroscience/Drug Abuse Research Program (2005) 168:53-79. [cited by applicant]
Nagai, Hiroshi, et al., “Antipsychotics improve A9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice,” Pharmacology, Biochemistry and Behavior (2006)84:330-336. [cited by applicant]
Puighermanal, Emma, et al., “Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling,” Nature Neuroscience (2009) 12(9):1152-1160. [cited by applicant]
Wiley, Jenny, “Age-dependent differences in sensitivity and sensitization to cannabinoids and ‘club drugs’ in male adolescent and adult rats,” Addiction Biology (2007) 13:277-286. [cited by applicant]
Marx, C. E. et al., Neuropsychopharmacology (2009) 34(8):1885-1903. [cited by applicant]